Season 3 - Ep.23: Strategic decisions in valvular heart disease - Optimising drug therapy in chronic coronary syndromes

13 snips

Sep 25, 2025

Dive into recent cardiology insights as experts discuss fulminant myocarditis outcomes and the surprising benefits of beta blockers in heart failure with COPD. Explore innovative TAVI strategies for bicuspid aortic stenosis and the importance of specialized heart valve centers. Learn about the shift in TAVI age recommendations and effective management of mitral regurgitation. Plus, uncover the latest in anti-anginal drugs and the intriguing question: does wearing a white coat really enhance intelligence?

Ask episode

AI Snips

Chapters

Transcript

Episode notes

INSIGHT

High Early Mortality In Fulminant Myocarditis

Fulminant myocarditis carries high in-hospital mortality, especially with giant cell histology.
Survivors who leave hospital often show excellent long-term recovery and function.

INSIGHT

Beta Blockers Safe In HFrEF With COPD

Beta blocker use in HFrEF with COPD linked to 24% fewer heart-failure events without increasing COPD exacerbations.
Registry data are observational but help reduce safety concerns about beta blockers in COPD patients.

INSIGHT

TAVI Valve Types Have Trade-Offs

Balloon-expandable and self-expanding TAVI valves show different procedural trade-offs but similar death/stroke rates up to three years.
Choice between valve types depends on residual regurgitation, gradients, pacemaker risk and anatomy.

Get the Snipd Podcast app to discover more snips from this episode

Get the app

This episode covers:

Cardiology This Week: A concise summary of recent studies
Strategic decisions in valvular heart disease
Optimising drug therapy in chronic coronary syndromes
Mythbusters: Does wearing a white coat make you smarter?

Host: Susanna Price

Guests: John-Paul Carpenter, Fabien Praz, Robert Storey

Want to watch that episode? Go to: https://esc365.escardio.org/event/2092

Want to watch that extended interview on Optimising drug therapy in chronic coronary syndromes ? Go to: https://esc365.escardio.org/event/2092?resource=interview

Disclaimer:

ESC TV Today is supported by Bristol Myers Squibb and Novartis.

This scientific content and opinions expressed in the programme have not been influenced in any way by its sponsors.

This programme is intended for health care professionals only and is to be used for educational purposes.

The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC.

The ESC is not liable for any translated content of this video. The English-language always prevails.

Declarations of interests:

Stephan Achenbach, Yasmina Bououdina, Nicolle Kraenkel, Fabien Praz and Susanna Price have declared to have no potential conflicts of interest to report.

Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede.

John-Paul Carpenter has declared to have potential conflicts of interest to report: stockholder Mycardium AI.

Davide Capodanno has declared to have potential conflicts of interest to report: Bristol Myers Squibb, Daiichi Sankyo, Sanofi Aventis, Novo Nordisk, Terumo.

Konstantinos Koskinas has declared to have potential conflicts of interest to report: honoraria from MSD, Daiichi Sankyo, Sanofi.

Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada.

Robert Storey has declared to have potential conflicts of interest to report: research grants and personal fees from AstraZeneca and Cytosorbents, and personal fees from Abbott, Afortiori Development/Thrombolytic Science, Boehringer Ingelheim/Lilly, Bristol Myers Squibb/Johnson & Johnson, Chiesi, Idorsia/Viatris, Novo Nordisk, PhaseBio and Tabuk.

Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.